Innovating Healthcare: Cedars-Sinai’s Blueprint for Ventures in the US

  • co11ab
  • investment, technologies, trends, strategies
  • March 28, 2025
Innovating Healthcare: Cedars-Sinai’s Blueprint for Ventures in the US

co11ab co-hosted a dynamic panel discussion featuring leaders from Cedars-Sinai and π—–π—Όπ—Ώπ—Όπ—»π—²π˜ π—©π—²π—»π˜π˜‚π—Ώπ—²π˜€, as they shared timely insights on emerging trends and strategic investments in the U.S. health tech ecosystem.

The lively discussion was further enriched by our moderator, Clarice Chen from Enterprise Singapore, whose charismatic and impactful facilitation helped the audience better understand Cedars-Sinai’s capabilities and key focus areas, including regenerative medicine, biomanufacturing, and clinical trials.

Cedars-Sinai’s growing presence in Singapore reflects their confidence in our vibrant healthtech and biomedtech landscape. Together with our founding partners, co11ab is proud to play a catalytic role in connecting global and local players through strategic partnerships and impactful programming.

Β 

As we continue to strengthen our ecosystem locally and internationally, we look forward to more meaningful collaborations to help startups grow, scale, and succeed.

Thank you to our speakers:
πŸ’ Nirdesh K Gupta, PhD Gupta (Managing Partner, Cedars-Sinai & CEO Coronet Ventures)
πŸ’ Colin Tan (Investment Director, Coronet Ventures)
πŸ’ Wenyue Du, PhD, CLP (Director of Business Development – Biomedical, Cedars-Sinai)
πŸ’ Julien Brohan (Director of Business Development – Medtech, Cedars-Sinai)
πŸ’ Clarice Chen (Director of Healthcare & Biomedical, Enterprise Singapore)

Latest News & Events

Subscribe To Our Newsletter

Join our mailing list to get updated with our latest news and events!

Contact Information
  • Lee Kong Chian School of
    Medicine,
    Clinical Sciences Building
    11 Mandalay Road #16-01
    Singapore 308232

  • +65 6904 1401
Members Login

co11ab Novena (co11ab) is a Bio MedTech incubator – forged through a tripartite alliance between Nanyang Technological University, Singapore (NTU Singapore), Agency for Science, Technology, and Research (A*STAR), and National Healthcare Group (NHG) – which aims to nurture and support the translational development of biomedical technologies. Our key focus areas are biotech, medtech and digital health.